Novel methodologic approaches to phase I, II, and III trials

Stroke

Volumn 44, Issue SUPPL. 1, 2013, Pages

  Yeatts, Sharon D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adaptive design; Clinical trial design; Continual reassessment method; Futility design; Selection design

Indexed keywords

DEFEROXAMINE MESYLATE;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COGNITION; CONFERENCE PAPER; DISEASE SEVERITY; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL INTERACTION; STUDY DESIGN;

ADAPTIVE DESIGN; CLINICAL TRIAL DESIGN; CONTINUAL REASSESSMENT METHOD; FUTILITY DESIGN; SELECTION DESIGN;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDICAL FUTILITY; RESEARCH DESIGN; STROKE; TREATMENT OUTCOME;

EID: 84880310048     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000031     Document Type: Conference Paper

References (18)

1. Hong KS, Lee SJ, Hao Q, Liebeskind DS, Saver JL. Acute stroke trials in the 1st decade of the 21st century. Stroke. 2011;42:e314.
2. Fisher M for the Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies. Stroke. 2005;36:1808-1813.
3. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45:925-937.
4. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46:33-48.
5. The IMS Trial Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke study. Stroke. 2004;35:904-912.
6. The IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007;38:2127-2135.
7. Palesch YY, Tilley BC, Sackett DL, Johnston KC, Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005;36:2410-2414.
8. Herson J, Carter SK. Calibrated phase II clinical trials in oncology. Stat Med. 1986;5:441-447.
9. Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med. 1994;13:417-429.
10. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66:660-663.
11. US Food and Drug Administration. Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2010; http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf Accessed October 31, 2012.
12. Chow SC, Chang M. Adaptive Sample Size Adjustment. In: Chow SC, ed. Adaptive Design Methods in Clinical Trials. Boca Raton, CL: Chapman & Hall; 2007: 137-159.
13. Chow SC, Chang M. Adaptive Randomization. In: Chow SC, ed. Adaptive Design Methods in Clinical Trials. Boca Raton, CL: Chapman & Hall; 2007: 47-73.
14. Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke. 2011;42:2356-2362.
15. Adams HP Jr., Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
16. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055-3062.
17. Cella D, Nowinski C, Peterman A, Victorson D, Miller D, Lai JS, et al. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil. 2011;92:S28-S36.
18. Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol. 2005;23:S53-S57.